The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 86 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 2.2 mo · strongest signal: Hearings panel (Sep 9, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (shelf effective, shelf filed, offering (424b)). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
bioAffinity Technologies (BIAF) disclosed on July 31, 2026 that Nasdaq issued a delisting notice for failing to maintain a minimum bid price above $1.00 for 30 consecutive days; the company is ineligible for any compliance period because it executed a 1-for-30 reverse split in September 2025 (Nasdaq rules permit one reverse split per 12 months). Two weeks later, on August 14, 2026, the company closed a $4M private placement of pre-funded warrants at $0.4657 plus accompanying Series A and B warrants (200% coverage) exercisable at $0.4727 (contingent on stockholder approval), with WallachBeth as placement agent. The 10-Q for Q2/2026 (filed August 7) showed cash of $2.4M as of June 30, 2026, implying approximately 2.2 months of runway based on annualized 180-day operating cash burn of $13M.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 80 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 9, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-09-09 filing | 48 |
| Sep 9, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-09 filing | 39 |
| Sep 9, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-09-09 filing | 34 |
| Sep 8, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-09-08; 5 prior 424B filings in 12m filing | 28 |
| Sep 4, 2026 | ▼ Shelf effective | EFFECT notice 2026-09-04 filing | 21 |
| Sep 3, 2026 | ▼ Shelf filed | S-3/A filed 2026-09-03 filing | 30 |
| Aug 27, 2026 | ▼ Shelf filed | S-3 filed 2026-08-27 filing | 30 |
| Aug 20, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-08-20 filing | 42 |
| Aug 20, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-08-20 filing | 39 |
| Aug 20, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-08-20 (accepted 08:30 ET) filing | 31 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~2.2 months runway: liquidity $2,429,719 as of 2026-06-30, burn $13,035,253/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 41 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 4,534,906 (2026-05-04) -> 8,101,725 (2026-08-03), +79% filing | 38 |
AUID authID Inc. · SOBR SOBR Safe, Inc. · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · screener →